Medexus Pharmaceuticals Inc. (MEDXF)

1.9600 0.0000 (0.00%) At close: 04:00PM EDT

Medexus Pharmaceuticals Inc.

10 King Street East
Suite 600
Toronto, ON M5C 1C3
Canada
877 422 5242
https://www.medexus.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 82

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Kenneth d'Entremont	CEO & Director	1.04M	N/A	N/A
Mr. Richard Labelle	Chief Operating Officer	345.6k	N/A	N/A
Mr. Ian C. Wildgoose Brown	General Counsel & Corporate Secretary	424.69k	N/A	N/A
Mr. Brendon Buschman	Chief Financial Officer	N/A	N/A	N/A
Ms. Tina Byers CFA	Executive of Investor Relations	N/A	N/A	N/A
Mr. Bill Poncy	Senior Vice President of Commercial Operations - United States	439.69k	N/A	N/A
Mr. Brian Peters	Vice President of Sales & Marketing - United States	294.96k	N/A	N/A

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.

Corporate Governance

Medexus Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.